CCAAT/enhancer-binding proteins (C/EBPs) are a family of highly conserved transcription factors that have important roles in normal myelopoiesis as well as associated with myeloid disorders. The chronic myelogenous leukemia (CML) cell lines, KCL22 and K562, express exceptionally low levels of endogenous C/EBPs and provide a good model to test the effects of C/EBPs on myeloid differentiation. To explore the possibility that C/ EBPd can promote differentiation in BCR-ABL-positive cells, we generated stable KCL22 and K562 clones that expressed an inducible C/EBPd gene. C/EBPd expression resulted in G0/G1 proliferative arrest and a moderate increase in apoptosis of the KCL22 and the K562 cells. Within 4 days of inducing expression of C/EBPd, myeloid differentiation of the CML blast cells occurred as shown by morphologic changes and induction of secondary granule-specific genes. We also showed that during granulocytic differentiation of KCL22 cells, the C/EBPd protein was detected in immunocomplexes with both Rb and E2F1. Furthermore, expression of C/EBPd was associated with downregulation of c-Myc and cyclin E and upregulation of the cyclin-dependent kinase inhibitor p27
Introduction
C/EBPd belongs to the CCAAT/enhancer-binding protein (C/EBP) family of transcriptional regulators that function in tissue differentiation, metabolism, and immune responses. Members of the C/EBP family are structurally related, each consisting of an N-terminal transactivation region, a central basic DNA-binding domain, and a C-terminal leucine zipper motif for dimerization (Ramji and Foka, 2002) . C/EBPd has been implicated in control of adipogenesis, differentiation of pneumocytes, and myelomonocytic cells as well as mediating the acute-phase response to inflammatory stimuli (Cao et al., 1991; Scott et al., 1992; Breed et al., 1997; Tanaka et al., 1997; Cantwell et al., 1998) . In addition, C/EBPd plays a key role in the G0/G1 growth arrest of mammary epithelial cells (O'Rourke et al., 1999) .
Within hematopoiesis, C/EBPa, C/EBPb, and C/EBPd are predominantly expressed in the granulocyte, monocyte, and eosinophil lineages; and C/EBPe is found in the middle-to-later-stages of differentiation of granulocytes and T cells (Scott et al., 1992; Friedman 2002) . C/EBP isoforms are also expressed in multiple myeloid leukemia cell lines. Overexpression of C/EBPa, C/EBPb, C/EBPd, or C/EBPe can induce granulocytic differentiation in myeloblastic cell lines (Radomska et al., 1998; Park et al., 1999; Wang and Friedman 2002; Duprez et al., 2003) , suggesting that in myeloid cells, C/EBP family members can compensate in vivo for the lack of one of the other C/EBP proteins.
Chronic myelogenous leukemia (CML) is a clonal hematopoietic stem cell disorder caused by the BCR-ABL fusion oncogene. In the chronic phase of the disease, the leukemic cells retain the ability to differentiate into mature granulocytes; however, after a period of 3-5 years, CML often progresses to a fatal blast crisis, characterized by a profound block in differentiation. The molecular events underlying the transition from the chronic phase to the blast crisis are not completely understood (Ahuja et al., 1991; Mori et al., 1997; Asimakopoulos et al., 1999; Honda et al., 2000) . Recent studies suggest that deregulation of C/EBPs in cells expressing BCR-ABL plays a key role in the BCR-ABL-induced block in differentiation (Perrotti et al., 2002; Schuster et al., 2003) . The KCL22 and K562 cell lines were established from bone marrow cells of an individual with blast crisis BCR-ABL-positive CML. Previously, we showed that, unlike normal myeloid progenitor cells, KCL22 cells contain low levels of C/EBPe, but no functional C/EBPa, C/EBPb, or C/EBPd Verbeek et al., 1999; Vegesna et al., 2002) . Similarly, the multipotent K562 cells do not express detectable levels of C/EBPa, C/EBPb, C/EBPd, or C/EBPe (Radomska et al., 1998; Kubota et al., 2001; Duprez et al., 2003) . These findings are unique because almost all human myeloid cell lines express several C/EBPs. These two cell lines provide a good model to determine the effect of forced expression of one member of the C/EBP family in the absence of other C/EBPs confounding the analysis.
To test the possibility that C/EBPd can promote neutrophilic differentiation in BCR-ABL-positive cells and to understand more clearly the molecular mechanisms underlying this process, we stably transfected KCL22 and K562 cells with an inducible C/EBPd gene. Our results show that ectopic expression of C/EBPd leads to growth arrest, increase in apoptosis, and neutrophilic differentiation. At the molecular level, expression of C/EBPd in the CML KCL22 and K562 cells was associated with downregulation of c-Myc and cyclin E and upregulation of the cyclin-dependent kinase inhibitor p27Kip1.
Results

C/EBPd expression during normal granulocytic differentiation
We used DNA microarray analysis to examine the expression of C/EBPd mRNA levels upon induction of lineage-specific differentiation of normal CD34 þ bone marrow cells. The results showed that C/EBPd mRNA is upregulated during granulocytic differentiation, suggesting that C/EBPd is involved in this process (Table 1, GAPDH expression levels at each time point was essentially unchanged, data not shown). These data agree with earlier studies that have shown temporal expression of C/EBPd in myeloid lineages using traditional methods of studying gene expression (Scott et al., 1992) .
Expression of C/EBPd in KCL22 and K562 cells
To examine the possibility that C/EBPd can promote neutrophilic differentiation in BCR-ABL-positive CML cells, the human C/EBPd cDNA expression vector under the control of a zinc-inducible metallothionein promoter was stably transfected into KCL22 and K562 cells. Several independent G418-resistant subclones were obtained by limiting dilutions. Expression of C/EBPd was up to 10 days. Cell morphology was examined daily by cytospin and staining with Wright-Giemsa. Within 4-7 days of zinc treatment, many of the KCL22-pMTd cells underwent myeloid maturation ( Figure 2a ). Most of the cells had a reduction in their nuclear to cytoplasmic ratio with more condensed nuclear chromatin, and some had segmented nuclei typical of mature granulocytes. In contrast, the morphology of KCL22-pMT cells grown in the presence of zinc did not change (data not shown).
In different cell types, C/EBPd can be found either in the cytoplasm in an inactive form, or in the nucleus where it can be functionally active (Billiard et al., 2001) . DAPI staining and immunohistochemistry with a C/ EBPd antibody were used to determine the localization of C/EBPd in the KCL22 cells. Results showed that by day 4 of zinc treatment, C/EBPd was located in the nuclei of the differentiating KCL22-pMTd cells ( Figure 2b ). The nuclear localization of C/EBPd suggests an active role of this transcription factor in the differentiating KCL22 cells.
Morphological differentiation was also accompanied by upregulation of neutrophil-specific genes, as analysed by RT-PCR. Total RNA extracted from KCL22-pMTd and K562-pMTd cells, cultured either with or without zinc, was subjected to RT-PCR with specific primers for collagenase and G-CSFR. In the absence of zinc, collagenase and G-CSFR transcripts were undetectable in the KCL22-pMTd and the K562-pMTd cells. Culturing the cells in zinc-containing media resulted in a dramatic increase in the levels of these granulocyterelated genes ( Figure 2c ). Real-time PCR was also performed on selected days to ensure quantitative induction of gene expressions. Western blot analysis showed that G-CSFR protein levels were also induced in the KCL22-pMTd and K562-pMTd cells cultured in zinc-containing media ( Figure 2d) . In contrast, G-CSFR protein was undetectable in the KCL22-pMT and K562-pMT cells grown in the presence of zinc. Induction of C/ EBPd expression in the KCL22-pMTd and K562-pMTd cells also led to upregulation of CD11b, a cell surface marker associated with myeloid differentiation (Figure 2e ).
C/EBPd induced G0/G1 growth arrest and increased apoptosis in KCL22 and K562 cells
The effect of C/EBPd on cell growth was examined by viable cell counts. KCL22-pMT, KCL22-pMTd, K562-pMT, and K562-pMTd cells were cultured either in the presence or absence of zinc for 6 days and counted daily. The control pMT cells proliferated rapidly both in the presence and the absence of zinc (Figure 3a ). In contrast, the proliferative rate of KCL22 and K562 cells, which were induced to express C/EBPd, decreased remarkably.
We also examined the affect of C/EBPd expression on the cell cycle of the CML cells. KCL22-pMT, KCL22-pMTd, K562-pMT, and K562-pMTd were grown in the presence of zinc and analysed by FACS (Figure 3b) . By day 4 of C/EBPd induction, the KCL22-pMTd and K562-pMTd cells had an increased number of cells (73 and 75%, respectively) in the G0/G1 phase and a decreased number of those (17 and 18%, respectively) in the S phase of the cell cycle compared with control KCL22-pMT (53%, G0/G1 and 35%, S phase) and K562-pMT (55%, G0/G1 and 34%, S phase) cells.
We next tested whether expression of C/EBPd induced apoptosis of the KCL22 and K562 cells. The stable cell lines were grown with zinc for 6 days and tested for apoptosis using TUNEL assay. Modestly greater apoptosis was observed in the C/EBPd-expressing KCL22-pMTd (12%) and K562-pMTd (17%) cells as compared to the control KCL22-pMT (5%) and K562-pMT (6%) cells (Figure 3c ).
Soft agar assays were used to determine whether the effects of C/EBPd on differentiation and cell growth were reversible. KCL22-pMT, KCL22-pMTd, K562-pMT, and K562-pMTd were grown in liquid culture either with or without zinc for 4 days; equal numbers of cells were plated in soft agar either in the presence or absence of zinc and resulting colonies were counted after 2 weeks (Figure 3d) . Incubation of the KCL22-pMTd and K562-pMTd cells in zinc-containing media led to complete inhibition of colony formation (0 colonies). Exposure of the KCL22-pMT and K562-pMT control cells to zinc also inhibited colony formation compared with untreated cells, but to a significantly lesser extent. Of note, treatment of KCL22-pMTd and K562-pMTd cells with zinc in liquid culture for 4 days, washing the cells and plating them in media without zinc, did not cause an inhibition of clonogenic growth in soft agar. These experiments demonstrate that the effects associated with brief (4 day) induction of C/EBPd are reversible. The ability of the KCL22-pMTd and K562-pMTd cells to grow on soft agar following transit expression of C/EBPd showed that these cells were still viable, although the majority of the cell population had been arrested in the G0/G1 phase of the cell cycle in liquid culture ( Figure 3B ).
C/EBPd interacts with E2F1 and Rb in KCL22 cells
Studies found that the ability of C/EBPs to regulate differentiation and cell growth in various cell types depended, at least in part, on their ability to interact with the cell cycle proteins Rb and E2F (Chen et al., 1996; Timchenko et al., 1999; Slomiany et al., 2000; Gery et al., 2004) . We, therefore, examined whether C/ EBPd can bind Rb and/or E2F1 in KCL22 cells. Protein extracts from KCL22-pMT and KCL22-pMTd cells, which were grown with zinc, were immunoprecipitated with either Rb or E2F1 antibodies followed by Western analysis with a C/EBPd antibody. The results showed that upon induction of C/EBPd, this protein could be found in both Rb and E2F1 immunocomplexes in these CML cells (Figure 4a, b) .
C/EBPd represses expression of c-Myc and cyclin E
Previous studies suggested that the interactions between C/EBPs and E2F transcription factors results in down-regulation of c-Myc (Johansen et al., 2001; Gery et al., 2004) and possibly cyclin E (Gheorghiu et al., 2001) . We consequently tested the possibility that C/EBPd regulates c-Myc and cyclin E expression in KCL22 and K562 CML cells. Western blots analysis showed that in the presence of zinc, levels of c-Myc and cyclin E protein decreased in the KCL22-pMTd and K562-pMTd cells, compared to controls (Figure 4c ). 
C/EBPd upregulates p27
Kip1 expression
A previous study showed that overexpresson of C/EBPd leads to an increase in the cyclin-dependent kinase inhibitor p27 Kip1 in mammary epithelial cells (O'Rourke et al., 1999). We, therefore, examined whether induction of C/EBPd in KCL22 and K562 cells can affect p27 expression. KCL22-pMT, KCL22-pMTd, K562-pMT, and K562-pMTd cells were cultured in the presence of zinc and expression levels of p27 Kip1 mRNA were measured by real-time PCR with specific primers (Figure 5a ). Results showed that by day 2 of zinc treatment, the p27 mRNA level was eight fold higher in the C/EBPd-expressing KCL22-pMTd cells compared with the KCL22-pMT control cells. A four fold induction in p27 mRNA level was seen on day 2 of zinc treatment in the K562-pMTd cells, relative to levels of p27 in the zinc-treated K562-pMT control cells.
Western blot analysis showed that the increase in p27 mRNA expression was followed by an increase in p27 protein expression (Figure 5b ).
Discussion
In the present study, we investigated the effect of ectopic expression of C/EBPd on BCR-ABL-positive CML cells. Morphologic changes consistent with terminal myeloid differentiation occurred within 4 days of C/ EBPd expression. These morphologic changes were accompanied by the transcription of myeloid-specific genes (collagenase and G-CSFR), induction of expression of CD11b, arrest in cell proliferation, and an increase in apoptosis. Perrotti et al. (2002) suggested that in blast crisis of CML, BCR-ABL blocks granulocytic differentiation by downregulation of C/EBPa expression. In addition, recent results suggested that BCR-ABL induces a reversible blocks in differentiation by disrupting C/EBPa and C/EBPe function (Schuster et al., 2003) . The BCR-ABL-positive CML blast crisis-derived cell line KCL22 does not express active C/EBPa, C/EBPb, or C/EBPd Verbeek et al., 1999; Vegesna et al., 2002) , and offers an opportunity to study the activities of the different C/EBP family members. A second BCR-ABL-positive CML cell line, K562, is widely used as a model of hematopoietic cell differentiation as it is capable of differentiating along several hematopoietic lineages. Similar to KCL22, K562 cells do not express detectable levels of the C/EBP proteins. We hypothesized that the block in differentiation of KCL22 and K562 cells might result from the lack of functional C/EBPs in these cells. Indeed, ectopic expression of C/EBPa or C/EBPb in K562 cells drives the cells to differentiate into mature granulocytes (Perrotti et al., 2002; D'Alo' et al., 2003; Duprez et al., 2003) . Furthermore, in a recent study, we showed that restoration of C/EBPa in KCL22 cells leads to dramatic granulocytic differentiation (Tavor et al., 2003) . Taken together, these results suggest that expression of one of several C/EBP family members is sufficient to induce granulocytic differentiation in BCR-ABL-positive cells, and further establish a role for the C/EBP transcription factors as master regulators of myeloid differentiation.
To elucidate the molecular mechanisms leading to C/EBPd-induced differentiation and growth arrest, we tested the possibility that C/EBPd interacts with the cell cycle regulator proteins Rb and E2F1. Previous studies showed that interaction between C/EBP family members and these two proteins plays critical roles in several differentiation systems where C/EBPs have been implicated (Chen et al., 1996; Timchenko et al., 1999; Slomiany et al., 2000; Gery et al., 2004) . Our data demonstrated that upon induction of C/EBPd, this protein could be detected in complexes with Rb and E2F1 in KCL22 cells. Further studies will determine what role the C/EBPd-Rb/E2F1 interactions play in C/EBPd-induced differentiation and growth arrest in KCL22 cells. One of the consequences of the C/EBPa-and possibly C/EBPe-E2F interactions is downregulation of c-Myc that is mediated through an E2F site in the c-Myc promoter (Johansen et al., 2001) . The proto-oncogene cmyc plays a pivotal role in regulating hematopoietic homeostasis (Hoffman et al., 2002) . Downregulation of expression of c-Myc is critical for granulopoiesis, while upregulation of levels of c-Myc by BCR-ABL inhibits myeloid differentiation. A recent study suggested that in 32Dcl3 cells, deregulation of c-Myc by BCR-ABL inhibits C/EBP-dependent transcription and differentiation (Schuster et al., 2003) . We found that similar to C/ EBPa and C/EBPe, expression of C/EBPd results in a decrease in c-Myc protein levels. These data suggest that the downregulation of c-Myc plays an important role in the ability of C/EBPs to overcome the BCR-ABL block in differentiation. We also found that cyclin E protein levels were reduced in the C/EBPd-overexpressing cells. A previous study showed that C/EBPs bind to E2F4 in intestinal cells and suggested that this led to decreased expression of E2F target genes such as cyclin E (Gheorghiu et al., 2001) .
Expression of C/EBPd in the growth-arrested KCL22 and K562 cells was associated with an increase in mRNA and protein levels of the cyclin-dependent kinase inhibitor p27Kip1. Earlier studies demonstrated that expression of C/EBPd in mammary cells results in G0/ G1 growth arrest and apoptosis along with upregulation of p27 expression (O'Rourke et al., 1999; Billiard et al., 2001) . These results suggest that C/EBPd regulates growth in different cell types by influencing p27 levels. The decrease in cyclin E and increase in p27 levels observed in the C/EBPd-overexpressing-KCL22 and -K562 cells could be directly regulated by C/EBPd, or indirectly through the downregulation of c-Myc. Previous studies showed that c-Myc suppressed the p27 promoter and induced the expression of the cyclin E gene (Perez-Roger et al., 1997; Yang et al., 2001 ). In addition, inhibition of c-Myc followed by downregulation of cyclin E and upregulation of p27 are important early events in regulating cell cycle arrest of myeloid cells (Dimberg et al., 2002; Schuster et al., 2003) .
The coordinated expression of the various C/EBPs constitutes a critical component of the myeloid differentiation program (Scott et al., 1992; Yamanaka et al., 1998; Friedman 2002) . Forced expression of either C/ EBPa, C/EBPb, C/EBPd or C/EBPe in hematopoietic cells is sufficient for granulocytic differentiation in myeloid cell lines (Radomska et al., 1998; Park et al., 1999; Wang and Friedman 2002) , indicating that C/EBP family members can compensate for the lack of a specific subtype. However, the phenotype of knockout mice lacking one or more C/EBP proteins demonstrates that endogenously expressed C/EBP members may not always substitute for the absence of a specific C/EBP isoform (reviewed in Yamanaka et al., 1998) . Adding to this complexity, we have found that hematopoiesis including granulopoiesis appears to be normal in mice where C/EBPb was knocked into the C/EBPa locus replacing the latter (Jones et al., 2002) .
In summary, our data indicate that expression of C/ EBPd in CML BCR-ABL positive cells is sufficient to stimulate myeloid maturation. In addition, we found that KCL22 and K562 cells induced to express C/EBPd exhibited a decrease in levels of c-Myc and cyclin E and an increase in p27 expression, as well as an accelerated G0/G1 growth arrest and apoptosis. Elucidating the role that C/EBPs play in blast crisis cells of CML in combination with developing either small molecules to induce selectively their expression or delivery systems to introduce these transcription factors into target cells, may provide novel therapeutic approaches to this disease.
Materials and methods
Microarray expression analysis
CD34 þ bone marrow cells were selected from healthy individuals (day 0) by density separation and reliance on expression of CD34 using superparamagnetic streptavidin microparticles as previously described . These cells were divided into three pools. One pool was stimulated in vitro with G-CSF (20 ng/ml), GM-CSF (20 ng/ ml), SCF (50 ng/ml), Flt3-Ligand (50 ng/ml), and IL-3 (10 ng/ ml) to induce granulocyte and monocyte lineage-specific differentiation. The second pool was cultured with erythropoietin (10 U/ml), SCF (50 ng/ml), Flt3-Ligand (50 ng/ml), and IL-3 (10 ng/ml) to stimulate erythroid differentiation; the third received thrombopoietin (20 ng/ml), SCF (50 ng/ml), and Flt3-Ligand (50 ng/ml) to enhance production of megakaryocytes. At days 0, 4, 7, and 11, cells were harvested for expression profiling. In cases where the purity of the target cells was below 50%, the cells were purified by immunomagnetic beads prior to expression profiling. CD11b antibody was used for selection of granulocyte/monocyte cells; selection of erythroid and megakaryocytes cells relied on CD71 and CD61, respectively. Gene expression was analysed by oligonucleotide microarrays (HG-U133A, Affymetrix, Santa Clara, CA, USA). Owing to the low amounts of total RNA, a double in vitro transcription protocol (nanogram scale assay) was used as described previously . The experiments were performed in triplicates for each of the time points and each of the conditions. Data analysis was performed with the GeneSpring software version 4.2 (Silicon Genetics, San Carlos, CA, USA).
Plasmids and transfections
The zinc-inducible C/EBPd expression vector (pMTd) was constructed by inserting a full-length human C/EBPd cDNA at the HindIII and KpnI sites of pMTCB6 þ vector (pMT, a kind gift from FJ Rauscher, III, The Wistar Institute, Philadelphia, PA, USA). KCL22 (ATCC; Rockville, MD, USA) and K562 (purchased from the ATCC) cells were transfected with either pMTd (KCL22-pMTd) or pMT (KCL22-pMT, as a control), using an electroporation apparatus (Electro Square Porator T820, BTX, San Diego, CA, USA). Selection with G418 at 1 mg/ml was started 48 h after electroporation to obtain stably transfected cells. Multiple monoclonal cultures were screened for zinc-inducible C/EBPd expression by Western blot analysis.
Western analysis
Cells were lysed with lysis buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 0.5% NP-40), subsequently cell lysates were resolved on 4-15% gradient sodium dodecyl sulfate-polyacrylamide gels (SDS-PAGE) and transferred to nitrocellulose membranes (Sigma). Immunoblots were incubated with various primary antibodies followed by incubation with appropriate anti-rabbit or anti-mouse secondary IgG antibody conjugated with horseradish peroxidase (Amersham Pharmacia Biotech). SuperSignal West Pico substrate (Pierce) was used for detection. The following primary antibodies were used: anti-C/EBPd (sc-158), anti-G-CSFR (sc-694), anti-Rb (sc-102), anti-E2F1 (sc-251), anti-c-Myc (sc-764), anti-p27 (sc-528), anti-cyclin E (sc-247) from Santa Cruz Biotechnology, and anti-GAPDH from Research Diagnostics. Western blots were stripped between hybridizations with stripping buffer (10 mM Tris-HCl pH 2.3, 150 mM NaCl).
Immunoprecipitation
Protein extracts were incubated with either an Rb antibody (sc-102AC) or an E2F1 antibody (sc-251AC) at 4 1C for 16 h. The precipitated proteins were washed three times with PBS, eluted with SDS sample buffer and subjected to Western blot analysis as described above.
Cell differentiation and morphological analysis and immunohistochemistry
The cellular morphology of KCL22-pMTd cells was studied after Wright-Giemsa staining of cytospin slides. For immunohistochemistry, KCL22-pMTd cells cultured on coverslips were fixed in 4% paraformaldehyde, permeabilized with À20 1C methanol and subsequently blocked with 1% BSA. The cells were then labeled with C/EBPd antibody, washed with PBS and incubated with a phycoerythrin (PE)-conjugated secondary anti-rabbit IgG. After washing with PBS, the samples were mounted and examined under the fluorescent microscope. DAPI staining was preformed using the Actin Cytoskeleton and Focal Adhesion Staining Kit (Chemicon, Temecula, CA, USA) according to the manufacture's interactions. Expression of the CD11b was evaluated with a specific PE-conjugated mouse monoclonal antibody (Pharmingen, San Diego, CA, USA). Results were analysed on a FACscan flow cytometer (Beckton Dickinson, Mountain View, CA, USA).
Cell proliferation, cell cycle analyses, apoptosis assays and soft agar assays KCL22-pMT, KCL22-pMTd, K562-pMT, and K562-pMTd cells (5 Â 10 4 ) were grown either with or without ZnSO 4 (100 mM) for 6 days. The mean number of viable cells was determined daily using trypan blue exclusion. Cell cycle analyses were performed on KCL22-pMT, KCL22-pMTd, K562-pMT and K562-pMTd cells incubated with ZnSO 4 (100 mM) for 4 days. The cells were fixed in cold ethanol, stained with 50 mg/ml PI, 1 mg/ml RNase, and 0.1% NP-40 and analysed by FACScan and CELLFit program (Becton Dickinson). Apoptosis was detected by terminal deoxynucleotidyltransferase-mediated UTP end labeling TUNEL technique using in situ Cell Death Detection Kit (Boehringer Mannheim) according to the manufacturer's protocol. For clonogenic assays, KCL22-pMT, KCL22-pMTd, K562-pMT, and K562-pMTd cells were either treated or untreated with ZnSO 4 (100 mM) for 4 days. Cells (2 x 10 4 cells/well) were then washed and plated in 0.3% agar either with or without ZnSO 4 over a 0.6% agar layer in 24-well plates. Resulting colonies were counted after 2 weeks.
RT-PCR and real-time RT-PCR
Total RNA (2 mg) was converted into cDNA using MMLV reverse transcriptase (Life Technologies, Inc.). Semiquantitative RT-PCR was performed to determine the expression levels of collagenase and G-CSFR using the following conditions: an initial denaturation step at 941C for 5 minutes followed by 25 cycles of 941C for 30 s, 601C for 40 s, and 721C for 1 min. RT-PCR for 18S was utilized as an internal control. Reaction products were visualized on ethidium bromidestained agarose gels, and images of PCR products were captured using AlphaImager 2000 Gel Documentation software. Expression levels of collagenase and G-CSFR as well as p27 mRNA were measured by real-time RT-PCR using HotMaster Taq DNA Polymerase (Eppendorf) and SYBRGreen I (Molecular Probes). Levels of 18S were measured for endogenous reference. PCR conditions were as follows: 2 min at 941C, followed by 45 cycles of 941C for 20 s, 601C for 10 s, 651C for 25 s and fluorescence determination at the melting temperature of the product for 20 s. Specificity of PCR products was checked on agarose gel. Reactions were performed in triplicates in an iCycler iQt system (Biorad, Hercules, CA, USA). For each sample, the amount of the target gene and 18S was determined from a standard curves.
